Norway, Jan. 8 -- Lifecare ASA (LIFE) announces a major system-level milestone, reporting the first in-vivo confirmation that its fully integrated implantable Continuous Glucose Monitoring (CGM) system functions as intended, using implants from the company's first reproducibly manufactured production batch.In practical terms, this means Lifecare's implant has now been shown to track glucose inside a living body using reproducibly manufactured implants, without relying on laboratory conditions or external calibration.The results were generated in Lifecare's ongoing longevity study LFC-SEN-002 and represent the first real-life operation of the company'scomplete implant architecture in living tissue, combining manufacturing reproducibility, bi...